Free Trial

Pfizer/BioNTech Study If 3rd Dose Raises Effectiveness Against Variants

GLOBAL

Wall St. Journal reporting that pharma giants Pfizer and BioNTech are conducting a small study to examine whether giving an individual a third dose of their mRNA-based COVID-19 vaccine can increase its effectiveness in combatting mutations of the COVID-19 vaccine from South Africa and other sources.

  • Article confirms that Pfizer/BioNTech and other firms such as Moderna and J&J are also working on tweaked vaccines in an attempt to make them more effective against new mutations of the virus.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.